Making the compound Amanitin available for cancer therapies

Our mission is to research and develop drugs for cancer patients to provide them
with a targeted, tailor-made and highly effective treatment option

ADC Drug Development

We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.

ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.


PR: Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
16 December 2022
PR: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022
14 December 2022
PR: Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022
10 November 2022
PR: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
07 November 2022

Meet us

Interview Effecten Spiegel
23 January 2023
ASH Annual Meeting 2022
10 December 2022
ADC Target Selection Summit
07 December 2022
German Equity Forum
30 November 2022

Partner Informationen

RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
3 January 2023
Read more
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
20 December 2022
Read more
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the ASH Annual Meeting
12 December 2022
Read more

© Heidelberg Pharma AG. All rights reserved.